RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases

Area of Science:

• Molecular Biology
• Immunology
• Vascular Biology

Background:

• Proteins in the TNF/TNF receptor families, identified in 1997, are key to bone remodeling.
• The molecular triad of osteoprotegerin (OPG), receptor activator of nuclear factor kappa B (RANK), and RANK ligand (RANKL) controls osteoclastogenesis.
• Knock-out and transgenic mice studies revealed unexpected roles for these factors in vascular and immune systems.

Purpose of the Study:

• To review current knowledge on OPG/RANK/RANKL interactions and their roles.
• To summarize evidence linking OPG/RANK/RANKL to osteoimmunology and vascular diseases.
• To discuss the therapeutic potential of targeting the OPG/RANK/RANKL axis.

Main Methods:

• Review of existing literature on OPG/RANK/RANKL.
• Analysis of data from knock-out and transgenic mouse models.
• Synthesis of findings across bone metabolism, vascular biology, and immunology.

Main Results:

• The OPG/RANK/RANKL triad is central to bone remodeling and osteoclastogenesis.
• These factors are implicated in vascular calcifications.
• The triad plays a critical role in immune system development, particularly via dendritic cells.

Conclusions:

• The OPG/RANK/RANKL axis acts as a molecular bridge between bone metabolism, vascular biology, and immunity.
• This triad is involved in osteoimmunology and vascular diseases.
• Targeting the OPG/RANK/RANKL axis presents promising therapeutic strategies.